קיופנס 200 מג
mbi pharma ltd., israel - trientine as dihydrochloride - קפסולה קשיחה - trientine as dihydrochloride 200 mg - trientine
ווילנטין 250 מג
trustpharm ltd, israel - trientine hydrochloride - קפסולות - trientine hydrochloride 250 mg - trientine
טריאנטין רז 250 מג
raz pharmaceutics ltd, israel - trientine dihydrochloride - קפסולות - trientine dihydrochloride 250 mg - trientine
טריאנטין הידרוכלוריד מדומי 250 מג כמוסות
medomie pharma ltd, israel - trientine hydrochloride - קפסולה קשיחה - trientine hydrochloride 250 mg - trientine
מקיניסט 0.5 מג
novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 0.5 mg - trametinib
מקיניסט 2 מג
novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 2 mg - trametinib
טפינלר 50 מג
novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 50 mg - dabrafenib
טפינלר 50 מג
novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 50 mg - dabrafenib
טפינלר 75 מג
novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 75 mg - dabrafenib
פלויקס 75 מג
sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid